José Ríos

Publications (78) View all

• Article: Mapping data predictors of a left ventricular outflow tract origin of idiopathic ventricular tachycardia with V3 transition and septal earliest activation.

  Csaba Herczku, Antonio Berruezo, David Andreu, Juan Fernández-Armenta, Lluis Mont, Roger Borràs, Elena Arbelo, Jose M Tolosana, Emilce Trucco, José Ríos, Josep Brugada
  [show abstract] [hide abstract]
  ABSTRACT: The proximity of the outflow tracts (OTs) frequently results in an overlap in surface electrocardiographic features of ventricular arrhythmias originating from this anatomic region, particularly when the transition occurs in lead V3. In addition, no reliable criteria to discriminate between a right ventricular OT (RVOT) and a left ventricular OT (LVOT) site of origin (SOO) are derived from intracardiac mapping. A series of 15 patients underwent ablation because of OT ventricular arrhythmias having a V3 transition, and a septal earliest activation on the RVOT was included in the study. Electrocardiographic and mapping data were collected to analyze accuracy in predicting the RVOT versus the LVOT SOO of the ventricular arrhythmia. A 10-ms isochronal map area in the RVOT was smaller in the RVOT SOO group (1.2 [0.4-2.1] versus 3.4 [2.4-3.9] cm2, respectively; P=0.004) and had a shorter perpendicular diameter (13 [7-17] versus 28 [20-29] mm; P=0.001) and a higher longitudinal/perpendicular axis ratio (1.04 [0.95-1.11] versus 0.49 [0.44-0.57]; P=0.001). A 10-ms isochronal map area>2.3 cm2 predicted an LVOT origin with 85.7% sensitivity and 87.5% specificity, whereas a longitudinal/perpendicular axis ratio<0.8 predicted an LVOT origin with 100% sensitivity and 100% specificity. Electrocardiography-derived parameters showed lower values of sensitivity and specificity. The distal coronary sinus activation mapping did not permit distinction between RVOT and LVOT SOO. The 10-ms isochronal map area and the longitudinal/perpendicular axis ratio accurately predict the RVOT versus the LVOT SOO in patients with OT ventricular arrhythmias, a V3 transition, and a septal earliest activation.
  Circulation Arrhythmia and Electrophysiology 05/2012; 5(3):484-91. · 6.46 Impact Factor
• Article: Total hip arthroplasty in HIV-infected patients: a retrospective, controlled study.

  E Tornero, S García, M Larrousse, X Gallart, G Bori, J Riba, J Rios, Jm Gatell, E Martinez
  [show abstract] [hide abstract]
  ABSTRACT: Although HIV-infected patients are at greater risk of presenting with ischaemic necrosis of the femoral head, there have been concerns about whether total hip arthroplasty (THA) may have worse outcomes than expected. From the Orthopedic and Trauma Surgery database we identified all patients who had undergone THA because of ischaemic necrosis of the femoral head from January 2001 until March 2010. Patient's diagnosis of HIV infection was confirmed at the time of arthroplasty by cross-matching with the HIV unit database. For every THA in HIV-infected patients, two THAs in patients not known to be HIV-infected, with the same diagnosis of ischaemic necrosis of the femoral head and having undergone surgery over the same period, were randomly selected. THAs were compared in HIV- and non-HIV-infected patients for surgical procedure, in-patient stay and long-term prognosis. There were 18 THAs in 13 HIV-infected patients and 36 THAs in 27 non-HIV-infected patients. No significant differences were observed in the mean time spent in surgery (106 vs. 109 minutes, respectively; P = 0.66), the need for red cell transfusion (1 vs. 4, respectively; P = 0.48) or the mean duration of hospitalization (7.8 vs. 9.4 days, respectively; P = 0.48). The two groups showed similar postoperative functional results, which were maintained until the end of the follow-up period (median 3.3 years in the HIV-positive group and 5.8 years in the HIV-negative group). Our study suggests that the outcome of THA in HIV-positive patients is not worse than that of HIV-negative patients, although future research on larger numbers of patients is required to confirm this.
  HIV Medicine 04/2012; 13(10):623-9. · 3.01 Impact Factor
• Article: A three-gene expression signature model for risk stratification of patients with neuroblastoma.

  Idoia Garcia, Gemma Mayol, José Ríos, Gema Domenech, Nai-Kong V Cheung, André Oberthuer, Matthias Fischer, John M Maris, Garrett M Brodeur, Barbara Hero, Eva Rodríguez, Mariona Suñol, Patricia Galvan, Carmen de Torres, Jaume Mora, Cinzia Lavarino
  [show abstract] [hide abstract]
  ABSTRACT: Neuroblastoma is an embryonal tumor with contrasting clinical courses. Despite elaborate stratification strategies, precise clinical risk assessment still remains a challenge. The purpose of this study was to develop a PCR-based predictor model to improve clinical risk assessment of patients with neuroblastoma. The model was developed using real-time PCR gene expression data from 96 samples and tested on separate expression data sets obtained from real-time PCR and microarray studies comprising 362 patients. On the basis of our prior study of differentially expressed genes in favorable and unfavorable neuroblastoma subgroups, we identified three genes, CHD5, PAFAH1B1, and NME1, strongly associated with patient outcome. The expression pattern of these genes was used to develop a PCR-based single-score predictor model. The model discriminated patients into two groups with significantly different clinical outcome [set 1: 5-year overall survival (OS): 0.93 ± 0.03 vs. 0.53 ± 0.06, 5-year event-free survival (EFS): 0.85 ± 0.04 vs. 0.042 ± 0.06, both P < 0.001; set 2 OS: 0.97 ± 0.02 vs. 0.61 ± 0.1, P = 0.005, EFS: 0.91 ± 0.8 vs. 0.56 ± 0.1, P = 0.005; and set 3 OS: 0.99 ± 0.01 vs. 0.56 ± 0.06, EFS: 0.96 ± 0.02 vs. 0.43 ± 0.05, both P < 0.001]. Multivariate analysis showed that the model was an independent marker for survival (P < 0.001, for all). In comparison with accepted risk stratification systems, the model robustly classified patients in the total cohort and in different clinically relevant risk subgroups. We propose for the first time in neuroblastoma, a technically simple PCR-based predictor model that could help refine current risk stratification systems.
  Clinical Cancer Research 02/2012; 18(7):2012-23. · 7.74 Impact Factor
• Source

  Available from: José Ríos

  Article: Better outcomes in severe and morbid obese patients (BMI > 35 kg/m2) in primary Endo-Model rotating-hinge total knee arthroplasty.

  Luis M Lozano, Vicente López, José Ríos, Dragos Popescu, Pere Torner, Félix Castillo, Francisco Maculé
  [show abstract] [hide abstract]
  ABSTRACT: The Endo-Model rotating-hinge prosthesis is preferably indicated as a primary implant in patients with advanced axial deviation of the lower limbs or unstable knees with severe bone defects. Outcomes were studied in 111 knees, operated in a three-year period; the mean followup was 28 months. Joint balance enhancement and limbs mechanical axis correction were achieved after surgery. There were 6 deep infections and 16 patients referred postoperative anterior knee pain. WOMAC index scores disaggregated by gender and BMI showed better outcomes in obese patients (specifically, those with a BMI of 35-40 kg/m(2)) and in men. Although the lack of a control group did not allow definite conclusions and despite a nonnegligible complication rate, our results reveal that the Endo-Model total knee arthroplasty can be a useful tool to deal with severe and morbid obese patients affected of severe gonarthrosis associated with marked axial deviations, ligament instability, or bone defects.
  TheScientificWorldJOURNAL 01/2012; 2012:249391. · 1.66 Impact Factor
• Article: Bioequivalence study of 2 orodispersible formulations of ondansetron 8 mg in healthy volunteers.

  M Cánovas, J Rios, G Domenech, J Cebrecos, P Pelagio, M Canals, F Polonio, F Cabré
  [show abstract] [hide abstract]
  ABSTRACT: This study was designed to compare the rate and extent of absorption of 2 oral formulations of ondansetron (CAS 99614-02-5) 8 mg orodispersible tablets in healthy volunteers. 22 subjects were administered ondansetron orodispersible tablets of test and reference formulation in a single-dose, 2-period, 2-sequence, fasting, open-label, crossover and randomised study. Plasma concentrations were determined by LC/MS/MS. Log-transformed AUCs and Cmax values were tested for bioequivalence based on the ratios of the geometric means (test/reference). Tmax was analysed nonparametrically. The 90% confidence intervals of the geometric mean values for the test/reference ratios for AUC0-t and Cmax were within the bioequivalence acceptance range of 80-125%. According to the European Guideline [1] it may be therefore concluded that test formulation of ondansetron 8 mg orodispersible tablet is bioequivalent to the reference formulation.
  Arzneimittel-Forschung 01/2012; 62(2):59-62. · 0.72 Impact Factor